Invention Grant
- Patent Title: Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient
-
Application No.: US15532465Application Date: 2015-12-02
-
Publication No.: US10746726B2Publication Date: 2020-08-18
- Inventor: Kouji Matsushima , Satoshi Ueha , Satoru Ito , Shoji Yokochi , Yoshiro Ishiwata
- Applicant: The University of Tokyo , IDAC Theranostics, Inc.
- Applicant Address: JP Tokyo JP Tokyo
- Assignee: THE UNIVERSITY OF TOKYO,IDAC THERANOSTICS, INC.
- Current Assignee: THE UNIVERSITY OF TOKYO,IDAC THERANOSTICS, INC.
- Current Assignee Address: JP Tokyo JP Tokyo
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@b0a80d9
- International Application: PCT/JP2015/083855 WO 20151202
- International Announcement: WO2016/088791 WO 20160609
- Main IPC: A61K39/00
- IPC: A61K39/00 ; G01N33/50 ; C12Q1/68 ; G01N33/49 ; C12Q1/04 ; G01N33/68 ; G01N33/48

Abstract:
Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.
Public/Granted literature
Information query